Blood-brain disposition and antinociceptive effects of [D- penicillamine2,5]enkephalin in the mouse

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1151-1159

  Chen, Cuiping ^a   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; DELTA OPIATE RECEPTOR; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; TRITIUM;

ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; BRAIN LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG RECEPTOR BINDING; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANALGESICS, OPIOID; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, D-PENICILLAMINE (2,5)-; ENKEPHALINS; MALE; MICE;

EID: 0031444228     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. BANKS, W. A., AUDUS, K. L. AND DAVIS, T. P.: Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. Peptides 13: 1289-1294, 1992.
2. 2 (Tyr-W-MIF-1) is transported from the brain to the blood by peptide transport system-1. J. Neurosci. Res. 35: 690-695, 1993.
3. 2,5]enkephalin in rats. J. Chromatogr. Biomed. Appl. 681: 363-373, 1996.
4. 2,5]enkephalin in rats. Pharm. Res. 14: 345-350, 1997.
5. GIBALDI, M. AND PERRIER, D.: Pharmacokinetics, Marcel Dekker, Inc., New York, NY, 1982.
6. HEISEY, S. R.: Brain and choroid blood volumes in vertebrates. Comp. Biochem. Physiol. 26: 489-198, 1968.
7. LOH, H. H., TSENG, L. F., WEI, E. AND LI, C. H.: Beta-endorphine is a potent analgesic agent. Proc. Natl. Acad. Sci. U.S.A. 73: 2895-2898, 1976.
8. MOSBERG, H. I., HURST, R., HRUBY, V. J., GEE, K., YAMAMURA, H. I., GALLIGAN, J. J. AND BURKS, T. F.: Bis-penicillamine possess highly improved specificity toward delta opioid receptors. Proc. Natl. Acad. Sci. U.S.A. 80: 5871-5874, 1983.
9. MULLER, S. AND HOCHHAUS, G.: Metabolism of dynorphine A 1-13 in human blood and plasma. Pharm. Res. 12: 1165-1170, 1995.
10. PARDRIDGE, W. M., TRIGUERO, D., YANG, J. AND CANCILLA P. A.: Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J. Pharmacol. Exp. Ther. 253: 884-894, 1990.
11. 5]enkephalin in the mouse. J. Pharmacol. Exp. Ther. 241: 393-241, 1987.
12. SHAH, M. V., AUDUS, K. L. AND BORCHARDT R. T.: The application of bovine brain microvessel endothelial-cell monolayers grown onto polycarbonate membranes in vitro to estimate the potential permeability of solutes through the blood-brain barrier. Pharm. Res. 6: 624-627, 1989.
13. 2,5]enkephalin into the central nervous system: saturation kinetics and specificity. J. Pharmacol. Exp. Ther. 280: 1235-1240, 1997.
14. 5]enkephalin analogues with increased affinity and selectivity for δ opioid receptors. J. Med. Chem. 33: 249-253, 1990.
15. 5]enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. J. Pharmacol. Exp. Ther. 263: 1308-1316, 1992.
16. 5]enkephalin and two halogenated analogs after intravenous administration. J. Pharmacol. Exp. Ther 259: 1109-1117, 1991.
17. 5]enkephalin opioid analogs. J. Pharmacol. Exp. Ther. 266: 1649-1655, 1993.
18. 2,5]enkephalin, across the blood-brain and the blood-cerebrospinal fluid barriers. J. Neurochem. 66: 1289-1299, 1996.